跳至主要内容
临床试验/NCT00535951
NCT00535951已完成1 期

A Phase IB, Open-Label, Multicenter Study to Investigate the Effect of Oral LBH589 on Dextromethorphan, a CYP2D6 Substrate, and to Assess the Efficacy and Safety of Oral LBH589 in Patients With Advanced Solid Tumors

Novartis Pharmaceuticals5 个研究点 分布在 2 个国家目标入组 18 人开始时间: 2007年11月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
18
试验地点
5
主要终点
Pharmacokinetic (PK) parameters

研究概览

简要总结

This study will investigate the effect of oral LBH589 on dextromethorphan, a CYP2D6 substrate, and to assess safety and efficacy of oral LBH589 when used with this co-medication in advanced stage NSCLC or malignant pleural mesothelioma patients

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

LBH589

Experimental

干预措施: LBH589 (Drug)

结局指标

主要结局

Pharmacokinetic (PK) parameters

时间窗: first 10 days

次要结局

  • Safety (until disease progression, unacceptable toxicity or study completion) assessed by duration of patient participation(first 10 days, day 10 through end of treatment plus follow-up)
  • Response rate assessed by comparing tumor size via radiology scans (CTs or MRIs)(day 10 through end of treatment)
  • Tolerability (until disease progression, unacceptable toxicity or study completion) assessed by duration of patient participation(day 10 through end of treatment)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (5)

Loading locations...

相似试验